

PROFFERED ABSTRACTS

PR001 A092 **Reinforcing acinar identity through NR5A2 enables pancreatic cancer interception by preventing and reversing precancer**, Sahar Nissim, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA, United States

PR002 A097 **Surveillance-detected pancreatic cancers: Updated report from the PRECEDE Consortium**, Raymond Wadlow, Inova Health System, Fairfax, VA, United States

PR003 A049 **Mutant GNAS-mediated epithelial IL-33 upregulation promotes IPMN initiation and progression.**, Yuki Makino, The University of Osaka Department of Gastroenterology and Hepatology, Suita, , Japan

PR004 A117 **Inflammation links KRAS-driven tumor biology to adverse host phenotypes in pancreatic cancer**, Dina L Tataran, University of Glasgow, Glasgow, , United Kingdom

PR005 A057 **The basal cell state maintains pancreatic cancers by controlling an immunosuppressive cell circuit**, Kate Ryan, Memorial Sloan Kettering Cancer Center, New York, NY, United States

PR006 A072 **A time-to-event model for pancreatic cancer risk prediction across multiple future intervals using longitudinal structured electronic health records**, Jifan Gao,Dana-Farber Cancer Institute, Boston, MA, United States

PR007 B034 **Integrated spatial proteomics of human PDAC uncovers an expanded tumour-immune-stroma spectrum with genomic associations**, Noor Shakfa, Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada

PR008 B044 **EMT-associated focal adhesion signaling mediates resistance to RAS inhibition**, Joshua H Choe, Dana-Farber Cancer Institute, Boston, MA, United States

PR009 B092 **CD4+ T cells instruct cancer-associated fibroblasts to promote immune control of pancreatic cancer**, Jessica Hung, University of California, Berkeley, CA, United States

PR010 B118 **A mutant KRAS-targeted peptide vaccine in combination with RAS(ON) multi-selective inhibition and immune checkpoint modulators enhances anti-tumor**

immunity in preclinical PDAC models, Zirui Zhu, Johns Hopkins University, Baltimore, , United States

PR011 B049 **Digenic CRISPR screening identifies novel KRAS/FGFR combination therapies for pancreatic cancer**, Richard Y Ebright, Broad Institute, Boston, MA, United States

PR012 B057 **Encoding adaptive mechanisms of resistance to KRAS inhibition in pancreatic cancer**, Qingxiang Lin, Massachusetts General Cancer Center, Boston, MA, United States

PR013 B039 **Navlimetostat (BMS-986504) with or without gemcitabine (GEM) + nab-paclitaxel (nab-P) in patients (pts) with pancreatic ductal adenocarcinoma (PDAC) and homozygous MTAP deletion (MTAP-del) from CA240-0007**, Tanios Bekaii-Saab, Mayo Clinic, Phoenix, AZ, United States

PR014 B040 **Integrated translational analyses of the first generation KRAS G12D degrader setidegrasib identify mechanisms of response and resistance and offers rational combination strategies in pancreatic cancer**, Wungki Park, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center and David M. Rubenstein Center for Pancreatic Cancer Research, Weill Cornell Medical College, Parker Institute for Cancer Immunotherapy, New York, NY, USA, New York, NY, United States

PR015 B030 **Clonal Heterogeneity in Human Pancreatic Ductal Adenocarcinoma and Its Impact on Tumor Progression**, Sungsik Kim, UC San Diego, La Jolla, CA, United States

PR016 B032 **High-plex spatial phenotyping resolves immune organization in pancreatic ductal adenocarcinoma**, Deniz G Olgun, Massachusetts General Hospital, Boston, MA, United States

POSTER SESSION A

Saturday, September 26, 2026, 6-8 p.m.

A001 **Improved Modeling of Pancreatic Ductal Adenocarcinoma (PDAC) Using High-Density Collagen Matrix**, Marc Abou Assali, University of California San Diego, San Diego, CA, United States

A002 **Transcriptional regulation and membrane sequestration of myeloid-derived TNF in pancreatic cancer**, Andrew M Adams, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, United States

A003 **Deep functional characterization of donor and patient-derived pancreatic normal and cancer associated fibroblasts and their responses to pan-RAS inhibition**, Farrah Ali, Henry Ford Pancreatic Cancer Center, Detroit, MI, United States

A004 **Stromal-targeting payloads are not functionally equivalent in pancreatic cancer: Decorin-armed VSV couples matrix remodeling with systemic immune reprogramming**, Sina Aslanabadi, LSU Health, New Orleans, LA, United States

A005 **Deciphering the Hierarchy of Notch Signaling in Pancreatic Ductal Adenocarcinoma**, Allison Bischoff, University of Michigan, Ann Arbor, MI, United States

A006 **A p38α MAPK-TCF21 axis regulates pancreatic stellate cell activation and stromal reprogramming in pancreatic cancer**, Sayan Chakraborty, Miller School of Medicine, University of Miami Health System, Miami, FL, United States

A007 **Spatial Single-Cell Multi-Omics Identifies Niche Modulated MIC-to-MCC Plasticity Underlying Pancreatic Cancer Hepatic Metastasis**, Xi Chen, State Key Laboratory of Genome and Multi-omics Technologies, Chongqing, , China

A008 **Patient-matched tumor organoid and fibroblast pairs from endoscopic ultrasound-guided fine-needle aspiration and surgical specimens of pancreatic ductal adenocarcinoma reconstitute stroma-driven chemoresistance**, Kyung Min Lee, Biomedical Research Institute, Seoul National University Hospital, Seoul, , Korea, Rep.

A009 **CEMIP-Mediated hyaluronic acid metabolism Drives PDAC Metastasis**, Hee Seung Lee, Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea, Seoul, , Korea, Rep.

A011 **Targeting tumor-associated macrophage vulnerabilities to enhance therapy in pancreatic cancer**, Carlo Marchetti, University of Colorado, Aurora, CO, United States

A012 **Investigating the heterogeneity of different KRAS point mutations on DRP1 activation and its regulation of the TME in pancreatic cancer**, Victoria A Remley, University of Virginia, Charlottesville, VA, United States

A013 **Tumor microenvironmental metabolites regulate cancer-associated fibroblast heterogeneity**, Simon Schwoerer, University of Chicago, Chicago, IL, United States

A014 **IGFBP-3 Neutralization Promotes Tumor Angiogenesis In a Murine Model Of PDAC**, Zachary Sechrist, University of Rochester Medical Center, Rochester, NY, United States

A016 **Aspirin Reprograms Pancreatic Stellate Cells to Suppress Tumor– Nerve Interaction in Pancreatic Cancer**, Sıla Sığırlı, Acibadem University, Istanbul, , Türkiye

A017 **Collagen stiffness shapes the stromal microenvironment architecture in pancreatic cancer in vitro models**, Enrica Soprano, Institute of Nanotechnology - NANOTEC - Consiglio Nazionale delle Ricerche (CNR), Lecce, , Italy

A018 **Cancer Associated Fibroblasts regulate Humoral Immunity and B Cell Education within Tertiary Lymphoid Structures**, Braden T Stevenson, University of Pittsburgh, Pittsburgh, PA, United States

A019 **Tumor Nutrient Stress Regulates Cancer-associated Fibroblast Heterogeneity**, Marta Storl-Desmond, University of Chicago, Chicago, IL, United States

A020 **Coronin 1C Orchestrates Stromal Remodeling and Immune Exclusion to Drive Therapeutic Resistance in Pancreatic Ductal Adenocarcinoma**, Sashikanta Swain, All India Institute of Medical Sciences Bhubaneswar, Bhubaneswar, , India

A021 **High-dimensional biopsy-derived proteomics identify tumor-intrinsic inflammatory phenotypes associated with short-term mortality in pancreatic ductal adenocarcinoma**, Gerik W. Tushoski-Alemán, University of Florida, Gainesville, FL, United States

A023 **Analysis of p53 function in a plastic injury-associated cell state suggests a noncanonical route to PDAC**, Laura D Attardi, Stanford University, Stanford, CA, United States

A024 **A plastic, MYC-dependent KRT17+/GATA6+ hybrid state drives chemoresistance and therapeutic vulnerability in pancreatic cancer**, Lyanne Delgado-Coka, Stony Brook University, Stony Brook, NY, United States

A025 **TSHZ2 is a regulator of the intermediate subtype of pancreatic adenocarcinoma**, David Escobar, Henry Ford Health system, Detroit, MI, United States

A026 **Bulk deconvolution analysis identifies subtype-specific methylation differences in pancreatic cancer patients**, Erin E Grundy, Emory University, Atlanta, GA, United States

A027 **Loss of the Y chromosome drives basal identity and metastatic potential via epigenetic reprogramming in pancreatic cancer**, Barbara M Grüner, West German Cancer Center, Essen, , Germany

A028 **Metastatic potential defines an orthogonal axis of transcriptomic heterogeneity that predicts chemotherapy response and tumor microenvironment architecture in pancreatic ductal adenocarcinoma**, Jesse Handler, Emory University, Atlanta, GA, United States

A029 **Chromatin accessibility profiling of human pancreatic tumors reveals epigenetic features of malignant and stromal cell subtypes**, Kevin Hawthorne, Oregon Health & Science University, Portland, OR, United States

A030 **IRF1-dependent plasticity shapes niche-specific pancreatic cancer cell fitness and immune context**, Michelle Kha, Washington University in St. Louis, St. Louis, MO, United States

A031 **Molecular basis of MYC-driven basal-squamous pancreatic cancer evolution**, Jennifer J Lee, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, United States

A032 **Elucidating the role of p53 in suppressing pancreatic ductal adenocarcinoma**, Jessica L Mann, Stanford University, Stanford, CA, United States

A033 **Gangliosides as regulators of the hybrid epithelial-mesenchymal phenotype in pancreatic ductal adenocarcinoma**, Ali G Moursy, Van Andel Institute, Grand Rapids, MI, United States

A034 **Spatial multi-omics defines cancer-like precursor lesions in human pancreas**, Jude O Okoye, University of Michigan, ANN ARBOR, MI, United States

A035 **Co-targeting emergent vulnerabilities to overcome FOLFIRINOX resistance in pancreatic cancer**, Brooke A Pereira, Garvan Institute of Medical Research, Sydney, , Australia

A036 **Elucidating MYC allelic imbalance and therapeutic response in pancreatic ductal adenocarcinoma via patient-derived organoids**, Audrey G Sawyer, University of Wisconsin-Madison, Madison, WI, United States

A037 **DeltaNp63 loss defines resistance to CDK7 inhibitors in basal pancreatic ductal adenocarcinoma**, Adrianne Wallace-Povirk, Henry Ford Health, Detroit, MI, United States

A038 **LINE-1 remodel pancreatic ductal adenocarcinoma metastatic plasticity**, Ching Ngar Wong, Massachusetts General Hospital, Boston, MA, United States

A039 **Epigenetic regulation of cellular heterogeneity and the tumor-immune landscape in pancreatic cancer**, Xueyan Wu, University Medical Center Göttingen, Göttingen, , Germany

A040 **Intratumor stem cell repertoire in pancreatic cancer**, Wa Xian, Wake Forest University, Charlotte, NC, United States

A041 **KRAS inhibition drives adaptive surfaceome remodeling and reveals ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancer**, Jonathan M DeLiberty, Dana-Farber Cancer Institute, Boston, MA, United States

A042 **ctDNA KRAS detection in pancreatic ductal adenocarcinoma: Platform concordance, sensitivity and clinical associations in a contemporary cohort**, Jennifer Guo, New York-Presbyterian/Weill Cornell Medical Center, New York, NY, United States

A043 **Allele Specific Characteristics of KRASQ61 Mutated Gastrointestinal Malignancies with Clinical Outcomes and Transcriptomic Features in Pancreatic Cancer**, Sacha El Khoury, MD Anderson Cancer Center, Houston, TX, United States

A044 **CLDN18.2 Expression and Associations with KRAS Mutation Status and Survival in PDAC**, Sacha El Khoury, MD Anderson Cancer Center, Houston, TX, United States

A045 **Transcriptional evidence of IPMN-lineage differentiation in GNAS- and RNF43-mutant pancreatic adenocarcinoma**, Krity Basnet, Rutgers-Jersey City Medical Center, Jersey City, NJ, United States

A046 **Mechanotransduction in pancreatic ductal adenocarcinoma: the role of the hERG1/β1integrin complex.**, Elisa Boccolucci, University of Siena, Siena, , Italy

A047 **Mechanistic dissection and inhibitor targeting of nutrient scavenging in pancreatic cancer**, Kirsten L Bryant, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

A048 **TGFBR2 dysfunction rewires cell cycle, MAPK signaling, and migration in pancreatic cancer**, Vincent M. Lam, University of Kansas Medical Center, Kansas City, KS, United States

A049 **Mutant GNAS-mediated epithelial IL-33 upregulation promotes IPMN initiation and progression.**, Yuki Makino, The University of Osaka Department of Gastroenterology and Hepatology, Suita, , Japan

A050 **NEIL2 regulates RNA polymerase II dynamics to suppress transcription–replication conflicts in pancreatic cancer**, Fan Meng, City of Hope National Medical Center, Duarte, CA, United States

A051 **CREB1 integrates EGFR/ERK and p38/LIF oncogenic inputs as a transcriptional convergence hub in pancreatic ductal adenocarcinoma**, Rohan Moniruzzaman, Department of Surgery, University of Miami, Miller School of Medicine, Miami, FL, United States

A052 **CA19-9 promotes liver metastasis of pancreatic cancer through E-selectin mediated seeding in mice**, Satoshi Ogawa, Salk Institute for Biological Studies, La Jolla, CA, United States

A053 **Defining THOC3 as a key dependency in basal-squamous pancreas cancer subtype specification and growth**, Hannah N Pettit, Columbia University, New York, NY, United States

A054 **MICAL2 promotes oncogenic Kras-induced pancreatic cancer initiation by regulating RAC1-mediated acinar to ductal metaplasia**, Nirakar Rajbhandari, University of California San Diego, La Jolla, CA, United States

A055 **Dissecting the role of GLP-1 signaling during PDAC initiation and progression**, Chunxiao Ren, Stanford University, Stanford, CA, United States

A056 **Targeting the mutant p53 cancer cell secretome sensitizes tumors to gemcitabine/nab-paclitaxel chemotherapy and reduces metastasis in pancreatic cancer.**, Shona Ritchie, Garvan Institute of Medical Research, Sydney, , Australia

A057 **The basal cell state maintains pancreatic cancers by controlling an immunosuppressive cell circuit**, Kate Ryan, Memorial Sloan Kettering Cancer Center, New York, NY, United States

A058 **UNC5B functions as a metastatic dependency in pancreatic ductal adenocarcinoma through SRC–ZEB1-driven invasion and epithelial-to-mesenchymal**

transition, Muhammad Sadeqi Nezhad, Wilmot Cancer Institute, Rochester, NY, United States

A059 **MYC biomolecular condensates contribute to PDAC classical-to-basal transition and immune evasion**, Qi Su, University of California, San Diego, La Jolla, CA, United States

A060 **Copper homeostasis and stress adaptation in pancreatic ductal adenocarcinoma**, Kuo-Hui Su, University of Toledo, Toledo, OH, United States

A061 **Spatial Whole-Transcriptome Profiling Reveals Immune-Suppressive Stromal Niches and Associated Ductal Tumor Cell-State Programs in Pancreatic Cancer**, Yuan Sui, Salk Institute for Biological Studies, San Diego, CA, United States

A062 **SFRP2 Silencing Restrains Pancreatic Cancer Growth and Enhances Survival Through Remodeling of the Tumor Microenvironment**, Olivia Sweatt, Medical University of South Carolina, Charleston, SC, United States

A063 **Lipid metabolism-driven remodeling of immune ecosystem promotes pancreatic cancer progression and metastasis**, Bo Tu, Eppley institute, omaha, NE, United States

A064 **Hub protein analysis identifies CAD as a mediator for drug resistance in pancreatic cancer**, Foram Vyas, University of Toronto, Toronto, ON, Canada

A065 **Mutant GNAS drives cAMP/PDE/AMP–pAMPK signaling and therapeutic synergy with combined CDK4/6 and RAS inhibition in mucinous pancreatic neoplasia**, Jonathan Weitz, UC San Diego, La Jolla, CA, United States

A066 **Toward early detection of pancreatic cancer: Somatic genomic profiling of early- and late-onset PDAC in a diverse cohort**, Enrique Velazquez-Villarreal, Integrative Translational Sciences, Beckman Research Institute, City of Hope, Duarte, CA, United States

A067 **Precision medicine-oriented analysis of RTK-RAS signaling in gemcitabine-treated pancreatic cancer using conversational artificial intelligence**, Enrique Velazquez-Villarreal, Department of Integrative Translational Sciences, Beckman Research Institute, City of Hope, Duarte, CA, United States

A068 **Downregulation of MEIS2 in Multiple Cancers and Its Correlation with Improved Overall Survival: A Potential Prognostic Biomarker**, Abdulrahman E Algarni, northern border university, Arar, , Saudi Arabia

A069 **Interpretable frequency-domain multiple-instance learning for survival prediction of pancreatic ductal adenocarcinoma**, Fabian Cano, Universidad Nacional de Colombia, Bogota, , Colombia

A070 **Clinical application of functional precision medicine for pancreatic cancer enables personalized treatment prioritization and identification of RAS-targeted combinations**, Edward Chow, KYAN Technologies, Singapore, , Singapore

A071 **Deep learning enabled 3D multi-omic analysis reveals molecular signatures of heterogeneous response to chemotherapy in pancreatic cancer**, André Forjaz, Johns Hopkins University School of Medicine, Baltimore, MD, United States

A072 **A time-to-event model for pancreatic cancer risk prediction across multiple future intervals using longitudinal structured electronic health records**, Jifan Gao, Dana-Farber Cancer Institute, Boston, MA, United States

A073 **TP53 mutant variant allele frequency improves machine-learning prediction of post-operative survival in pancreatic cancer and marks a proliferative transcriptional program**, Kshitij S Gaur, Medical College of Wisconsin, Milwaukee, WI, United States

A074 **Isolated pulmonary metastasis as the first site of progression predicts long-term overall survival in resected pancreatic adenocarcinoma**, Kshitij S Gaur, Medical College of Wisconsin, Milwaukee, WI, United States

A076 **Comparison of Urinary and Plasma Extracellular Small Noncoding RNA Profiles for Pancreatic Cancer Detection in a High-Risk Population**, Nicholas J Bevins, Craif USA, San Diego, CA, United States

A077 **Integrated biomarker analysis of circulating tumor cells, circulating tumor DNA and extracellular vesicles in a single blood draw: Longitudinal monitoring for pancreatic cancer**, Yu-Shu Cheng, University of Michigan, Ann Arbor, MI, United States

A078 **Predictive Biomarkers for Malignant Progression of Pancreatic Intraductal Papillary Mucinous Neoplasms**, Kranthi Kumar Chougoni, Hoag Memorial Hospital Presbyterian, Newport Beach, CA, United States

A079 **Leveraging a human chronic pancreatitis organoid biobank for pancreatic cancer interception**, Dannielle Engle, Salk Institute, La Jolla, CA, United States

A080 **Spatial transcriptomic analysis reveals obesity driven upregulation of inflammatory markers and matrix remodeling in healthy donor pancreas**, Tana Gazdik, Oregon Health & Science University, Portland, OR, United States

A081 **Prospective Evaluation of a Regulatory-Approved ApoA2-Isoform In Vitro Diagnostic Assay for Pancreatic Cancer Risk Stratification Toward Interception in a Community-Based Screening Cohort**, Kazufumi Honda, Nippon Medical School, Tokyo, , Japan

A082 **IFOCOM Pancreas AI: A deep learning–based artificial intelligence system for early detection and clinical decision support in pancreatic cancer**, MOUBARAK IBRAHIMA MADOUGOU, Nigeiren League Fight Against Cancer, Niamey, AK, Nigeria

A083 **Automated Processing of Up to 50 mL Urine Enhances Recovery of Low-Abundance KRAS G12V ctDNA for Early Detection of Pancreatic Cancer**, Nafiseh Jafari, nRichDX, Irvine, CA, United States

A084 **Cathepsin S Activity as a Biomarker for Early Detection of Pancreatic Cancer**, Utsav Joshi, UCSD, San Diego, CA, United States

A085 **Urinary microRNA Profiling Identifies Early Pancreatic Cancer Among Individuals at Increased Risk**, Tomoya Kawase, Department of Gastroenterology and Hepatology, Kawasaki Medical School, Kurashiki, , Japan

A086 **PancMAP: Pancreatic Morphology Analysis Pipeline for Early Detection of Pancreatic Ductal Adenocarcinoma**, Yeseul Kim, UT MD Anderson Cancer Center, Houston, TX, United States

A087 **Distinct age-specific prediagnostic metabolic trajectories in early- and late-onset pancreatic cancer: a nationwide longitudinal cohort study**, Yeo Gyeong Ko, Yonsei University College of Medicine, Seoul, , Korea, Rep.

A088 **EphA2 Proteolytic Fragment Links Early Detection, IPMN Progression, and Therapeutic Resistance in Pancreatic Cancer**, Naohiko Koshikawa, Institute of Science Tokyo, Yokohama, , Japan

A089 **Implementation of an early detection program for pancreatic cancer using electronic health record-based risk prediction models**, Tiffany Q Luong, Southern California Permanente Medical Group, Pasadena, CA, United States

A090 **Quantitative evaluation of changes to healthy pancreatic microanatomy across the human lifespan**, Valentina Matos-Romero, Johns Hopkins University, Baltimore, MD, United States

A091 **Single-cell spatial transcriptomics reveals reprograming molecular hallmarks of PanIN initiation and progression preceding histological changes**, Canh Hiep Nguyen, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States

A092 **Reinforcing acinar identity through NR5A2 enables pancreatic cancer interception by preventing and reversing precancer**, Sahar Nissim, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA, United States

A093 **Defining the histologic and molecular landscape of the human pancreas: A clinical, histopathologic, and transcriptomic multi-feature interactive atlas of donor pancreata**, Giada Pontecorvi, UT Southwestern Medical Center, Dallas, TX, United States

A094 **Mapping early Pancreatic Cancer evolution through enhancer reprogramming and transcription factor interactomes**, Shalini V Rao, Cancer Research UK, Cambridge Institute, Cambridge, UT, United Kingdom

A095 **Quantifying the burden of undiagnosed, untreated pancreatic cancer facilitated through automated computational review of abdominal imaging**, Chase A Shipp, Northwell Health, New Hyde Park, NY, United States

A096 **Glycosyltransferase B4GALNT3 drives LacdiNAc deposition as part of cellular reprogramming in pancreatic precancer**, Christopher Taranto, Vanderbilt University, Nashville, TN, United States

A097 **Surveillance-detected pancreatic cancers: Updated report from the PRECEDE Consortium**, Raymond Wadlow, Inova Health System, Fairfax, VA, United States

A098 **Preliminary results of the wearable devices and remote toxicity checks to predict health outcomes in pancreatic cancer (WATCH-PC) study**, Emil Hodzic-Santor, University of Toronto, Toronto, ON, Canada

A099 **Creating an interconnected pancreatic cancer research knowledge system using a Large Language Model and wiki publishing platform**, Bernard A Kroll, Orthogonal Data LLC, Scarsdale, NY, United States

A100 **A computational framework for integrating multiscale spatial data in intraductal papillary mucinous neoplasms**, Yang Liu, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

A101 **Genome-wide association study in Taiwanese Han uncovers OR1A1 as a metastasis suppressor in pancreatic ductal adenocarcinoma**, Yu-Huei Liu, China Medical University, Taichung, , Taiwan

A102 **Differential Gene Expression Overlap as a Predictive Biomarker of CAR T-Cell Therapy Response in Pancreatic Cancer and Lymphoma.**, Alibeth E Luna Alvear, Universidad de Puerto Rico, Mayaguez, , Puerto Rico

A103 **Development of the cellular therapy barrier framework (CTBF): A computational transcriptomic approach to stratify pancreatic adenocarcinoma for precision cellular immunotherapy**, Khaoula Mazouzi, MD ANderson Cancer Center, Houston, TX, United States

A104 **Transfer learning for Pancreatic ductal adenocarcinoma (PDAC) subtyping using extracellular vesicle RNA (evRNA)**, Dinelka Nanayakkara, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

A105 **The PASS-01 Challenge: Comparing Biomarkers for Treatment Selection in Advanced Pancreatic Cancer in a Randomized Controlled Trial**, Wei Quan, Princess Margaret Cancer Centre, Toronto, ON, Canada

A106 **Virtual Stromal Staining of Routine Histology as an Exploratory, Stroma-Aware Prognostic Readout in Pancreatic Cancer**, Megan Rothney, Pictor Labs, Inc., Los Angeles, CA, United States

A107 **Multi-Omic Single-cell Sequencing Reveals KMT2D Loss Activates AP-1-Driven Enhancer Reprogramming to Promote Epithelial-to-Mesenchymal Plasticity in Pancreatic Cancer**, Raghunath Ranga Sudharshan, University of Michigan, Ann Arbor, Ann Arbor, MI, United States

A108 **Circulating GDF-15 reflects KRAS variant and co-mutation biology in advanced pancreatic ductal adenocarcinoma**, Sargis Hovhannisyan, Cedars-Sinai Medical Center, Los Angeles, CA, United States

A109 **Urinary Metabolomic Signatures of Pancreatic Cancer Generalize Across Japanese and Thai Populations Despite Profound Baseline Divergence**, Taisuke Baba, Nagoya University, Nagoya, , Japan

A110 **The Identification of IGFBP-3 as a Clinically Relevant Target in the Treatment of PDAC-induced Skeletal Muscle Wasting and Testing the Efficacy of an Anti-IGFBP-3 Neutralizing Antibody**, Calvin L. Cole, University of Rochester Medical Center, Rochester, NY, United States

A111 **Understanding the interplay between ULK1/2 signaling and the RAS MAPK pathway**, Seamus E Degan, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

A112 **Leveraging autophagy and pyrimidine metabolism to target pancreatic cancer**, Suzanne Dufresne, Salk Institute for Biological Studies, La Jolla, CA, United States

A113 **Preoperative Geriatric Nutritional Risk Index Predicts Postoperative Morbidity and Mortality After Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: A NSQIP study.**, Samantha Pugliese, Northwell Health, New Hyde park, NY, United States

A114 **HSF1 supports LDLR expression and LDL-cholesterol uptake in pancreatic ductal adenocarcinoma**, Ahmad Hegazi, University of Toledo College of Medicine and Life Sciences, Toledo, OH, United States

A115 **HDAC1 inhibition unleashes adaptive metabolism in pancreatic cancer**, Zeribe C Nwosu, Cornell University, Ithaca, NY, United States

A116 **Mito-Met 10 remodels the pancreatic tumor microenvironment through MAVS activation and CD8+ T cell metabolic reprogramming**, Maria Poimenidou, MCW, Milwaukee, WI, United States

A117 **Inflammation links KRAS-driven tumor biology to adverse host phenotypes in pancreatic cancer**, Dina L Tataran, University of Glasgow, Glasgow, , United Kingdom

A118 **Leveraging metabolic restriction in cooperation with SHP2 deficiency to inhibit PDAC**, Michael VanSaun, University of Kansas Medical Center, Kansas City, KS, United States

A119 **Weight and muscle increase associated with neoadjuvant IL-1β and PD-1 blockade plus combination chemotherapy**, Peter Yu, NYU Langone, New York, NY, United States

A120 **Tumor-intrinsic MYC promotes a skeletal muscle-involving wasting phenotype in pancreatic ductal adenocarcinoma**, Tingting Zhang, Oregon Health & Science University, Portland, OR, United States

A121 **Turning cold pancreatic tumors hot: Antitumor activity of Annamycin is partially mediated by $CD8^+$ T cell cytotoxicity**, Angela Alistar, Atlantic Medical Group, Morristown Hospital, Morristown, NJ, United States

A122 **Fecal microbiota transplantation in Pancreatic Cancer: Phase 0 Trial early results**, Seyda Baydogan, HCA Medical City Arlington, Arlington, TX, United States

A123 **AI-PACED: A prospective feasibility study of automated risk stratification, AI-augmented serial imaging, and biobanking for early detection of sporadic pancreatic cancer**, Khurram Khaliq Bhinder, Mayo Clinic, Rochester, MN, United States

A124 **Prevalence, Treatment Patterns, and Outcomes of Organ Dysfunction at Diagnosis in Metastatic Pancreatic Ductal Adenocarcinoma: A Single-Institution Analysis of 3,022 Patients**, Emma Cismas, Weill Cornell Medicine, New York, NY, United States

A125 **External Control Arms: a vital strategy to create high quality scientific evidence with patient centric trial design for pancreatic cancer trials in light of introduction of highly effective targeted therapies.**, Ruthie Davi, Medidata, New York City, NY, United States

A126 **Armoring logic-gated CAR T cells with a membrane-tethered IL-12 booster: initial data from the EVEREST-2 study of A2B543 in patients with advanced pancreatic cancer**, Joel R Hecht, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, United States

A127 **Targeting replication stress in pancreatic cancer: results of a phase 1b trial of azenosertib and gemcitabine in second line pancreatic cancer after progression on FOLFIRINOX**, Brandon M Huffman, Dana-Farber Cancer Institute, Boston, MA, United States

A128 **Design of a Phase 2 basket trial to assess mifomelatide (TCMCB07) in GI cancer cachexia: A focus on pancreatic ductal adenocarcinoma (PDAC)**, Meghan Joly, Endevica Bio, Portland, OR, United States

A129 **Phasic Hedgehog Inhibition Primes the Pancreatic Tumor Microenvironment to Enhance Chemoimmunotherapy in Metastatic Pancreatic Ductal Adenocarcinoma: Results from the Phase 1b/2 NUMANTIA Trial**, Valerie S Kalluri, MD Anderson Cancer Center, Houston, TX, United States

A130 **LOKI-101-001: Phase 1, open-Label, first-in-human trial of intraperitoneal Lm-LLO-TT and gemcitabine in participants with unresectable pancreatic ductal adenocarinoma**, Chaoyuan Kuang, Albert Einstein College of Medicine, Bronx, NY, United States

A131 **A phase I trial of FAP-Exd (AVA6103), a Fibroblast Activation Protein (FAP)-enabled pre|CISION® peptide-drug conjugate delivering sustained tumor**

microenvironment (TME) release of exatecan in patients with FAP-positive solid tumors, Dave Liebowitz, Avacta Therapeutics, London, , United Kingdom

A132 **A Phase 2 Study to Investigate the Efficacy and Safety of Acoustic Cluster Therapy with Modified FOLFIRINOX in Patients with Locally Advanced and Borderline Resectable Pancreatic Cancer**, Erin Pierce, HonorHealth Research Institution, Scottsdale, AZ, United States

A133 **CASPER: A Phase Ib trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancer**, Lyndsey Sandow, Oregon Health and Science University, PORTLAND, OR, United States

A134 **Atebimetinib Reduces Tumor Volume and Preserves Body Mass: A Dual Mechanism for Extended Survival in Pancreatic Cancer**, Peter Vu, University of California San Diego, San Diego, CA, United States

A135 **Optimizing the metrics: Following progress in PNET and PDAC treatments with histology, stage, and time-specific relative survival rates**, Kawther Abdilleh, Pancreatic Cancer Action Network, El Segundo, CA, United States

A136 **Demystifying NIH peer review: The study section as partnership between reviewers and scientific review officers**, Dolores Arjona, Center for Scientific Review, National Institutes of Health, Bethesda, MD, United States

A137 **Chemotherapy utilization and outcomes in patients with metastatic pancreatic adenocarcinoma**, Preeti Bajaj, Revolution Medicines, Redwood City, CA, United States

A138 **The Association between Food Swamps and Pancreatic Cancer Mortality in Georgia**, Malcolm Bevel, Cancer Prevention, Control, and Population Health, Georgia Cancer Center, Department of Medicine, Medical College of Georgia, Augusta University, Augusta, GA, United States

A139 **SUMOylation Inhibition Synergizes with Irinotecan and Daraxonrasib to Treat Pancreatic Cancer**, Asimina Courelli, University of California, San Diego, La Jolla, , United States

A140 **Patient-derived organoids and precision medicine: Insights from the PASS-01 clinical trial in PDAC**, Amber N Habowski, CSHL, Cold Spring Harbor, NY, United States

A141 **Precision population cancer medicine for pancreatic ductal adenocarcinoma: A framework integrating genomics, artificial intelligence, theranostics, and**

population health, Melissa Heard, National Pancreas Foundation (NPF) Mississippi Chapter President, Hattiesburg, MS, United States

A142 **Circulating tumor DNA as a prognostic biomarker in PDAC: Insights from Real-World Data**, Daiane Hemerich Brennan, Bristol Myers Squibb, Madison, NJ, United States

A143 **Divergent Subtype Trajectories in Pancreatic Cancer: Age-Period-Cohort and Joinpoint Analysis of Surveillance, Epidemiology, and End Results Program (SEER) Data**, Douglas Monroe, NCI, ROCKVILLE, MD, United States

POSTER SESSION B

Sunday, September 27, 2026, 5-7 p.m.

B001 **Cancer-associated fibroblast p38α MAPK signaling coordinates collagen architecture and immune suppression to drive chemoresistance in pancreatic cancer**, Camille M Acevedo, University of Miami Miller School of Medicine, Miami, FL, United States

B003 **Developing an all-human model of perineural invasion in pancreatic cancer**, Regina A. Casimiro-Núñez, University of Michigan, Ann Arbor, MI, United States

B004 **IgG-Fcγ activating receptor signaling slows tumor progression in a genetically engineered mouse model of pancreatic cancer**, Jeremy B Foote, University of Alabama at Birmingham, Mountain Brook, AL, United States

B005 **Integrated profiling of pancreatic tumor interstitial fluid to develop blood-based early detection signatures**, Ralph Francescone, Henry Ford Health, Detroit, MI, United States

B006 **Actin Cytoskeleton Dynamics in Tumor Cells Orchestrate Stromal Desmoplasia and Immune Evasion in Pancreatic Cancer**, Bharti Garg, Moores Cancer centre, San Diego, CA, United States

B007 **Dissecting the interplay between cytotoxic T lymphocytes and the pancreatic cancer stroma**, Matteo Golo, Garvan Institute of Medical Research, Sydney, NSW, Australia

B008 **Pan-RAS-GTP inhibition disrupts the KRAS-SHH axis to reprogram cancer-associated fibroblast subtypes and reduce stiffness in pancreatic cancer**, Marie C Hasselluhn, Columbia University Irving Medical Center, New York, NY, United States

B009 **Invasion status parses composition of the human pancreatic cancer perineural niche**, Zainab Hussain, Memorial Sloan Kettering Cancer Center, New York, NY, United States

B010 **RUNX1/2-mediated chromatin accessibility governs the activation of cancer associated fibroblasts in pancreatic cancer**, Chang-il Hwang, University of California Davis, Davis, CA, United States

B011 **HMGA2 controls fibroblast skewing and immune infiltration in basal pancreatic cancer**, Sita Kugel, Fred Hutchinson Cancer Center, Seattle, WA, United States

B012 **Pan-RAS Inhibition Reprograms T Cell Immunity within the Pancreatic Adaptive Immune Microenvironment**, Rashmi J Kumar, University of Michigan, Ann Arbor, MI, United States

B013 **Interrogating and modeling progression of early pancreatic intraepithelial neoplasia**, Ellen M Langer, Oregon Health & Science University, Portland, OR, United States

B014 **Leveraging dynamic epigenetic landscapes to decode tumor-associated macrophages in pancreatic ductal adenocarcinoma**, Debbie K. Ledezma, University of California San Diego, La Jolla, CA, United States

B015 **Targeting myeloperoxidase delays pancreatic cancer growth and enhances chemotherapy response**, Tracy W Liu, West Virginia University, Morgantown, WV, United States

B016 **MHC-II expressing pancreatic tumor cells alter macrophage polarization through VEGFA-NRP1 signaling**, Tamara Lopez-Vidal, Johns Hopkins University School of Medicine, Baltimore, MD, United States

B017 **Immune engineering to enhance CAR T cell trafficking in pancreatic ductal adenocarcinoma**, Priyanila Magesh, University of Minnesota, Minneapolis, , United States

B018 **A targetable opioid/cancer associated fibroblast axis drives extracellular matrix remodeling and tumor aggressiveness in pancreatic cancer**, Kathryn E Maraszek, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States

B019 **GABA signaling in CAFs as a novel regulator of pancreatic cancer immunosuppression**, Ariana Musa de Aquino, Henry Ford Health, Deroit, MI, United States

B020 **Myofibroblasts induce neuroplasticity to promote pancreatic inflammation and cancer progression.**, Jeremy Nigri, CSHL, Cold Spring Harbor, NY, United States

B021 **Epigenetic Reprogramming of Intraductal Papillary Mucinous Neoplasms (IPMNs) by Pancreatic Cancer Associated Fibroblasts**, Hailee I Porter, University of Wisconsin-Madison, Madison, WI, United States

B022 **Targeting mRNA Translation to Enhance Neoantigen Landscapes and Tumor Immunity**, Kamini Singh, Montefiore Einstein Comprehensive Cancer Center, Easton, CT, United States

B023 **Fibulin-3 promotes tumor progression and microenvironment remodeling in CA19-9-expressing pancreatic ductal adenocarcinoma**, Hyemin Song, Salk Institute for Biological Studies, La Jolla, , United States

B024 **Senescent cancer-associated fibroblasts drive early-stage lymph node metastasis in pancreatic cancer through lactate-mediated metabolic-epigenetic rewiring**, Tianxing Zhou, Tianjin Medical University affiliated Cancer Institute & Hospital, Tianjin, , China

B025 **A spatial proximity-weighted algorithm (SPAN) defines reproducible tumor niches and a persister ecosystem underlying acquired resistance to pan-RAS inhibition in PDAC**, Alvaro Curiel-Garcia, Columbia University, New York, NY, United States

B026 **Multimodal spatial profiling uncovers cell state–associated receptor–ligand interactions in pancreatic ductal adenocarcinoma**, Sibyl Drissler, University of Toronto, Toronto, ON, Canada

B027 **"Form follows function": A new paradigm of pancreatic cancer progression**, William Gasper, UT Southwestern Medical Center, Dallas, TX, United States

B028 **HLA loss shapes sex-specific tumor-immune interfaces and subtype identity in pancreatic cancer**, Michael J Geuenich, Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada

B029 **SpatialGland: A novel gland-based spatial analysis of the tumor microenvironment to resolve immune-ductal cell interactions in primary PDAC.**, Ryan S Humphrey, Duke University, Durham, NC, United States

B030 **Clonal Heterogeneity in Human Pancreatic Ductal Adenocarcinoma and Its Impact on Tumor Progression**, Sungsik Kim, UC San Diego, La Jolla, CA, United States

B031 **Spatial profiling reveals distinct tumor and myeloid ecosystems across lung and liver metastases in pancreatic ductal adenocarcinoma**, Emily L Lasse Opsahl, University of Maryland, Baltimore, Baltimore, MD, United States

B032 **High-plex spatial phenotyping resolves immune organization in pancreatic ductal adenocarcinoma**, Deniz G Olgun, Massachusetts General Hospital, Boston, MA, United States

B033 **Integrating spatial biology and peripheral blood biomarkers to map treatment resistance in pancreatic ductal adenocarcinoma**, Deniz G Olgun, Massachusetts General Hospital, Boston, MA, United States

B034 **Integrated spatial proteomics of human PDAC uncovers an expanded tumour-immune-stroma spectrum with genomic associations**, Noor Shakfa, Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada

B035 **Integrative multi-omics and microbiome profiling reveals molecular and microbial heterogeneity in a diverse cohort of pancreatic ductal adenocarcinoma**, Enrique Velazquez-Villarreal, City of Hope Comprehensive Cancer Center, Duarte, CA, Duarte, CA, United States

B036 **Systematic Germline and Tumor Genomic Analysis for Gene Discovery in Familial Pancreatic Cancer**, Jingxiong Xu, Ontario Institute for Cancer Research, Toronto, ON, Canada

B037 **Spatial remodeling of the pancreatic tumor microenvironment following chemotherapy and ablative radiotherapy**, Todd A Aguilera, UT Southwestern, Dallas, TX, United States

B038 **Long-term outcomes following surgical resection in a three-center subset of a randomized phase II trial of dose-escalated radiotherapy for borderline resectable and locally advanced pancreatic cancer**, Todd A Aguilera, UT Southwestern, Dallas, TX, United States

B039 **Navlimetostat (BMS-986504) with or without gemcitabine (GEM) + nab-paclitaxel (nab-P) in patients (pts) with pancreatic ductal adenocarcinoma (PDAC) and homozygous MTAP deletion (MTAP-del) from CA240-0007**, Tanios Bekaii-Saab, Mayo Clinic, Phoenix, AZ, United States

B040 **Integrated translational analyses of the first generation KRAS G12D degrader setidegrasib identify mechanisms of response and resistance and offers rational combination strategies in pancreatic cancer**, Wungki Park, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center and David M. Rubenstein Center for Pancreatic Cancer Research, Weill Cornell Medical College, Parker Institute for Cancer Immunotherapy, New York, NY, USA, New York, NY, United States

B041 **MEK/ERK-dependent regulation of TFEB in response to chemotherapeutic stress**, Marie-Josee Boucher, University of Sherbrooke, Sherbrooke, QC, Canada

B042 **Pharmacophenotypic analysis of advanced pancreatic cancer patient-derived tumoroid models uncovers spatiotemporal drug resistance dynamics associated with single-agent and combination therapies**, Jarle Bruun, Oncosyne AS, Oslo, , Norway

B043 **Targeting dual CDK9 and KRASG12D selective inhibition as a novel combination therapy in pancreatic ductal adenocarcinoma**, Michela Cadarso, University of Wisconsin - Madison, Madison, WI, United States

B044 **EMT-associated focal adhesion signaling mediates resistance to RAS inhibition**, Joshua H Choe, Dana-Farber Cancer Institute, Boston, MA, United States

B045 **Plasma cfDNA 5-hydroxymethylcytosine signatures associate with treatment response and molecular subtype in BRCA-mutant pancreatic cancer**, Ceyda Coruh, ClearNote Health, San Diego, CA, United States

B046 **Pseudo-irreversible, pan-KRAS inhibitor BH-501284 achieves prolonged inhibition of KRAS signaling leading to deep and durable antitumor efficacy in mouse tumor models**, Jean Cui, BlossomHill Therapeutics, San Diego, CA, United States

B047 **CXCR4 synergizes with multi-RAS inhibition by overcoming T cell exclusion to enhance immunogenic cancer cell death in human pancreatic cancer slice culture**, Sheela R Damle, Fred Hutch Cancer Center, Seattle, WA, United States

B048 **Metabolic adaptations under high glucose enhance KRAS and lipid synthesis inhibitor efficacy in pancreatic cancer**, GOUTAM Dey, Case Western Reserve University, Cleveland, OH, United States

B049 **Digenic CRISPR screening identifies novel KRAS/FGFR combination therapies for pancreatic cancer**, Richard Y Ebright, Broad Institute, Boston, MA, United States

B050 **ERK1 splicing switch triggers lethal hyperactivation and overcomes KRAS inhibitor resistance in pancreatic cancer**, Luisa F Escobar-Hoyos, Yale University, NEW HAVEN, CT, United States

B051 **Monounsaturated fatty acids mediate sensitivity to Ras inhibitors**, Lesley P Ferguson, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, United States

B052 **Understanding latent resistance mechanisms and their phenotypes in pancreatic cancer organoids under KRASG12D inhibition**, Lauryn E Flannagan, University of Wisconsin-Madison, Madison, WI, United States

B053 **RAS(ON) inhibition, but not chemotherapy, sensitizes RAS mutant PDAC to immunotherapy via tumor microenvironment remodeling in preclinical models**, Lilit Grigoryan, Revolution Medicines, Redwood City, CA, United States

B054 **Combined RAS Inhibition and Immune Checkpoint Blockade Overcome NF-κB-Mediated Immune Evasion in Chemoresistant Pancreatic Cancer**, Kevin Christian Gulay, Moores Cancer Center, University of California San Diego, San Diego, CA, United States

B055 **Combinatorial drug screening identifies synergistic combinations that sensitize resistant PDAC cells to cuproptosis-inducer NSC 319726**, Janine Kaupe, German Cancer Research Center and Technical University of Munich, Munich, , Germany

B056 **SOAT1 inhibition by a covalent metabolite mimetic targets RAS maturation and pancreatic cancer**, Wenjun Lan, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, United States

B057 **Encoding adaptive mechanisms of resistance to KRAS inhibition in pancreatic cancer**, Qingxiang Lin, Massachusetts General Cancer Center, Boston, MA, United States

B058 **Combining RAS and splicing inhibition in pancreatic cancer**, Saurabh Mandal, Henry Ford Heath, Detroit, MI, United States

B059 **Loss of Cullin-RING Ligase 5 mediates resistance to RAS inhibition in pancreatic cancer**, Cassandra S Markham, Yale University, New Haven, CT, United States

B060 **From Resistance to Rescue: Allele-Informed Salvage Therapy Following Daraxonrasib Resitance in Pancreatic Cancer**, Thomas McFall, Medical College of Wisconsin, Mary Ann and Charles LaBahn Pancreatic Cancer Program, Milwaukee, WI, United States

B061 **Epigenetic EZH2 dependency in KRAS inhibitor-resistant PDAC cells**, Gonçalo Outeiro-Pinho, University of Bern, Bern, , Switzerland

B062 **Mutant Gnas confers resistance to KRAS inhibition via IL-33 in IPMN-derived PDAC**, Kohki Oyama, Laura and Isaac Perlmutter Cancer Center, New York University Grossman School of Medicine, NYU Langone Health, New York, NY, United States

B063 **Exploring combination therapies to overcome RAS inhibitor resistance in pancreatic cancer**, Vasiliki Pantazopoulou, Salk Institute, San Diego, , United States

B064 **xCT promotes SMAD signaling to induce gemcitabine resistance in KRAS-mutated pancreatic cancer**, Joon Seong Park, Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, , Korea, Rep.

B065 **Bioactive Compounds Derived from Alcea rosea Suppress KRAS-Driven Signaling and Cancer Stem Cell Plasticity in Pancreatic Ductal Adenocarcinoma**, Ruhban A Parry, University of Kashmir, Srinagar, , India

B066 **Convergent cell-state programs characterize BRCA2-reversion-independent resistance in pancreatic cancer**, Joan Miguel Romero, Rosalind and Morris Goodman Cancer Institute of McGill University, Montreal, QC, Canada

B067 **Dissection of the in vitro response landscape in PDAC under KRAS inhibition reveals co-occurring conserved and adaptive transcription programs**, Hendrik Schürmann, Department of Medical Oncology & Bridge Institute of Experimental Tumor Therapy (BIT) and Division of Solid Tumor Translational Oncology (DKTK), West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, , Germany

B068 **FYN and other Src family kinases antagonize response to RAS inhibition in pancreatic ductal adenocarcinoma**, Hsiu-Chi Ting, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, United States

B069 **Genetic co-gain in MYC and KRAS drives resistance to targeting KRAS signaling in pancreatic ductal adenocarcinoma**, Motoyuki Tsuda, Oregon Health and Science University, Portland, OR, United States

B070 **Adaptive KRAS-MAPK signaling mediates resistance to CD73 blockade in pancreatic ductal adenocarcinoma**, Khadija Turabi, University of Nebraska Medical Center, Omaha, NE, United States

B071 **Preclinical Evaluation of Tumor Treating Fields (TTFields) Applied with KRAS Inhibitors in Pancreatic Ductal Adenocarcinoma Models**, Itai Tzchori, Novocure Ltd, Haifa, , Israel

B072 **Resistance to the RAS inhibitor daraxonrasib due to the LZTR1 mutation in a KRAS G12D mutated pancreatic ductal adenocarcinoma patient-derived organoid model**, Alexa F. Viniotis, HonorHealth Research Institute, Scottsdale, AZ, United States

B073 **Rational combination strategies enhance the depth and durability of zoldonrasib antitumor response in preclinical models of KRAS G12D pancreatic cancer**, Urszula N Wasko, Revolution Medicines, REDWOOD CITY, CA, United States

B074 **Comparative analysis of next-generation KRAS inhibitors in patient derived pancreatic cancer organoids**, Paul G Winckler, Institute of Molecular Medicine and Cell Research, Freiburg im Breisgau, , Germany

B075 **Harnessing Tumor-Penetrating Peptides to Modulate the Pancreatic Tumor Immune Microenvironment**, Shawn Abeynaike, Moores Cancer Center - UC San Diego, La Jolla, CA, United States

B076 **Tumor cell-intrinsic KMT2D loss regulates T cell function through FN1 signaling in pancreatic ductal adenocarcinoma**, Heizel Acosta, University of Michigan, Ann Arbor, MI, United States

B077 **FOLFIRINOX Bolsters the Intratumoral and Systemic B Cell Activation Compared to Gemcitabine-Abraxane in Patients with PDAC**, Charu Arora, University of Pittsburgh, Pittsburgh, PA, United States

B078 **Developing an all-human preclinical model of PDAC immunoreactivity**, Peter A Azorsa, Immunology Graduate Program, University of Michigan, Ann Arbor, MI, United States

B079 **Comprehensive expression atlas of chemokine ligands and receptors reveals endothelial ACKRs as regulators of immune exclusion in human PDAC**, Ayush Bharati, Medical College of Wisconsin, MIlwaukee, WI, United States

B080 **Maturation-dependent sensing of microenvironmental cues drives divergent neutrophil polarity in pancreatic cancer**, Anna Bianchi, University of Miami Miller School of Medicine, Miami, FL, United States

B081 **Tumor-associated antigen-specific immune profiling reveals distinct immunological responses to chemotherapy in pancreatic ductal adenocarcinoma**, Silvia Brugiapaglia, University of Turin, Turin, , Italy

B082 **Viable pancreatic tumor resident microbes constrain antigen presentation and therapy responses**, Vidhi Chandra, UT MD Anderson Cancer Center, Houston, TX, United States

B083 **Mutant KRAS cooperates with the hypoxic tumor microenvironment to drive immunosuppressive macrophages via a paracrine PGE 2 /GM-CSF axis**, Matthew T Cribb, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

B084 **Tracking tumor-specific CD4 T cells in pancreatic cancer reveals an essential role for cognate interactions with myeloid cells in remodeling the tumor**

microenvironment following immunotherapy, Eduardo Cruz-Hinojoza, University of Minnesota, Minneapolis, MN, United States

B085 **Development of a Translational Manufacturing Strategy for a Novel CD4+ CD26+ mesoCAR T Cell Product for Pancreatic Ductal Adenocarcinoma Patients**, Della R Evans, Emory University, Atlanta, GA, United States

B086 **Mesothelin-targeted CAR Th1/17 cells are a novel cellular engineering platform for pancreatic cancer**, Delaney K Geitgey, Emory University School of Medicine, Atlanta, GA, United States

B087 **Impact of RAS inhibition on T cell maturation in the PDAC microenvironment**, Lauren Gerbereux, University of Michigan, Ann Arbor, MI, United States

B088 **Targeting bile acids mitigates PDAC Tumor Burden and induces anti-tumor immunity**, Erin Gibbons, The Wistar Institute, Philadelphia, PA, United States

B089 **Ferroptosis-associated iron-high pancreatic cancer cells downregulate interferon-induced MHC class II despite intact interferon signaling, limiting tumor antigen presentation to CD4+ T cells**, Minseon Gu, Yonsei University College of Medicine, Seoul, , Korea, Rep.

B090 **Defining The Immune Mechanisms Required For iRGD-guided Low Dose IL-2 Therapy in Pancreatic Ductal Adenocarcinoma**, Mika Harari, Scripps Research, Tenafly, NJ, United States

B091 **Tandem chimeric antigne receptor T cell therapies for the treatment of pancreatic cancer**, Priya Hays, Hays Documentation Specialists, San Mateo, CA, United States

B092 **CD4+ T cells instruct cancer-associated fibroblasts to promote immune control of pancreatic cancer**, Jessica Hung, University of California, Berkeley, CA, United States

B093 **Cytomegalovirus immunotherapy: A mutation agnostic approach for pancreatic cancer treatment.**, Tatiana Hurtado de Mendoza, University of California, San Diego, La Jolla, CA, United States

B094 **CDK12 inhibition activates cGAS-STING-mediated antitumor immunity and enhances immune checkpoint blockade in basal-like PDAC**, Dosuke Iwadate, The Institute of Medical Science, Asahi Life Foundation, Tokyo, , Japan

B095 **Discovery of treatment-associated peptide antigens for targeted immunotherapies in pancreatic ductal adenocarcinoma**, Weixi Kang, Massachusetts Institute of Technology, Cambridge, MA, United States

B096 **Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic cancer**, Sarah Kang, Broad Institute, Cambridge, MA, United States

B097 **Plectin promotes an aggressive phenotype and represses anti-tumor immunity in pancreatic cancer**, Kimberly A. Kelly, University of Virginia, Charlottesville, VA, United States

B099 **Tumor progression locus 2 kinase drives pancreatic cancer immune evasion through a MYBL2-CXCL10 signaling axis**, Huaping Li, Washington University School of Medicine in St. Louis, St. Louis, MO, United States

B100 **Targeting orthotopic and metastatic pancreatic cancer with allogeneic stem cell–engineered mesothelin-redirected CAR-engineered invariant natural killer T cells**, Yan-Ruide Li, University of California, Los Angeles, Los Angeles, CA, United States

B101 **Stroma-tumor crosstalk converges with oncogenic KRAS signaling to drive an NFκB-mediated immune evasion program**, Yuwenbin Li, Salk Institute for Biological Studies, La Jolla, CA, United States

B102 **Remote effects of gut stem cell IL-17 signaling on pancreatic tumor behavior**, Haoyue Liu, UT MD Anderson Cancer Center, Houston, TX, United States

B103 **Interleukin-1 Receptor Accessory Protein (IL1RAP) is a Critical Determinant of Neutrophil Trafficking in Pancreatic Cancer**, Harper M Marsh, University of Miami Miller School of Medicine, Miami, FL, United States

B104 **Pharmacological RAS inhibition synergizes with CAR T cells for tumor killing**, Jayne C McDevitt, University of Pennsylvania, Philadelphia, PA, United States

B105 **Multisite single-cell immune profiling of premetastatic pancreatic ductal adenocarcinoma in a prospective clinical trial**, Daniel Nussbaum, Duke University School of Medicine, Durham, NC, United States

B106 **Multiplexed cytokine and tumor-associated antigen mRNA immunotherapy for pancreatic ductal adenocarcinoma: Expanding antigenic breadth and tumor-targeted delivery toward clinical translation**, Chaitanya Parikh, ImmunoScript, Mansfield, MA, United States

B107 **Peptide-delivered low dose IL-2 reprograms pancreatic cancer immunity to improve survival**, In Hwan Park, UCSD-Moores Cancer Center, La Jolla, CA, United States

B108 **CXCR4 inhibition reprograms immune checkpoint networks and enhances anti-tumor immunity in patient-derived pancreatic cancer organoid–PBMC co-cultures**, ILENIA PELLICCIOTTA, Columbia University, NY, NY, United States

B109 **Proteomics analysis of histotripsy ablated pancreatic tumors in C57BL/6 mice.**, Joshua L Perez, Virginia Tech Carilion School of Medicine, Roanoke, VA, United States

B110 **Effector CD4 T cells convert transient responses to KRAS targeted therapy into long-term durable remissions in pancreatic cancer**, Li Qiang, Dana-Farber Cancer Institute, Boston, MA, United States

B111 **Convergent signaling via C/EBPβ activates neutrophilic MDSC- intrinsic NLRP3 Inflammasomes to drive stromal inflammation and chemoresistance in pancreatic cancer**, Karthik Rajkumar, University of Miami, Miami, FL, United States

B112 **Mast cell cross-talk with primary and metastatic pancreatic tumor cells**, Natalia Ramirez-Sotelo, University of Oklahoma Health Campus, Oklahoma City, OK, United States

B113 **Rewiring T cell signaling to activate STAT proteins in T cells that target pancreatic cancer**, Alejandra Rosario-Crespo, University of Michigan Medical School, Ann Arbor, MI, United States

B114 **Distinct Oncogenic KRAS Mutations Shape Tumor Immunity in Pancreatic Cancer**, Despina C Siolas, Weill Cornell Medicine, New York, NY, United States

B115 **Divergent T cell exhaustion dynamics in periphery versus tumor during neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma**, Umayal Sivagnanalingam, University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh, PA, United States

B116 **Myeloid cell co-activation via Dectin-1 and CD40 agonists coordinates non-classical mechanisms of T cell cytotoxicity in Pancreatic Ductal Adenocarcinoma**, Anna S Thickens, University of Pennsylvania, Philadelphia, PA, United States

B117 **From Epitranscriptomic to Metabolic Switch: PCIF1-Driven m6Am Modification Rewires Macrophage Lactate Metabolism to Orchestrate the Pancreatic Cancer Immune Microenvironment**, Qing Wang, Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, , China

B118 **A mutant KRAS-targeted peptide vaccine in combination with RAS(ON) multi-selective inhibition and immune checkpoint modulators enhances anti-tumor immunity in preclinical PDAC models**, Zirui Zhu, Johns Hopkins University, Baltimore, , United States

B119 **Generation of an Endogenous PDAC-Specific TCR Transgenic Mouse**, Chong Zuo, Dana Farber Cancer Institute, Boston, MA, United States

B120 **Enzyme-laden microcapsules for controlled starvation of tumors**, Makayla Allsberry, Department of Surgery, Division of Surgical Oncology, Moores Cancer Center, University of California San Diego, San Diego, CA, United States

B121 **Induction of Immunogenic Cell Death in Pancreatic Ductal Adenocarcinoma by a Sigma-2 Ligand–Conjugated xCT Inhibitor**, David Barr, Medical University of South Carolina, Charleston, , United States

B122 **The timing matters: schedule-dependent optimization of gemcitabine and RAS(ON) inhibition in pancreatic cancer, a call for a new approach to clinical trial design**, Jonathan Brody, Oregon Health & Science University, Portland, OR, United States

B123 **Oncostatin M receptor (OSMR) is a tumor-selective target in pancreatic ductal adenocarcinoma: Quantitative expression in primary and metastatic patient tumors.**, Naveenkumar Chandrashekhar, Medical College of Wisconsin, Milwaukee, WI, United States

B124 **Targeting the tumor microenvironment: A novel therapeutic strategy for pancreatic ductal adenocarcinoma**, Hui-Lan Chang, Acdemia Sinica, Taipei, , Taiwan

B126 **Targeting USP36 as a therapeutic strategy for high-MYC expressing pancreatic ductal adenocarcinoma**, Assmaa Elsheikh, Oregon Health and Science University, Portland, OR, United States

B127 **Synthetic Lethality Through Combined BET and CDK9 Inhibition in MYC-Amplified Pancreatic Ductal Adenocarcinoma.**, Paulina N Esguerra, University of Wisconsin Madison, Madison, WI, United States

B128 **Urolithin A enhances chemotherapy efficacy and preserves intestinal barrier integrity in pancreatic ductal adenocarcinoma**, Vineet K Gupta, Department of Surgery, University of Miami, Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, United States

B129 **Repurposed T-Box-Targeting Drug in Liposomal Formulation Shows Synergistic Efficacy Against PDAC**, Susan Immanuel, South Dakota State University, Brookings, SD, United States

B130 **Crossing dimensions: binding and penetration of LyP-1 in 3-D spheroids of pancreatic ductal adenocarcinoma tumors**, Charles Andre Jurisaga, University of California San Diego, San Diego, CA, United States

B131 **Application of proton beam therapy for pancreatic cancer at a single institution**, Jacob B. Leary, University of California San Diego, San Diego, CA, United States

B132 **MAT2A inhibition enhances the anti-tumor efficacy of combined pan-RAS(ON) and PRMT5 inhibition in MTAP-deficient pancreatic tumors**, Zhizhong Li, Puhe Biopharma, Beijing, , China

B133 **ROCK2 inhibition alters pancreatic cancer fibrosis and decreases metastasis.**, Niamh EP Mills, Garvan Institute, Sydney, NSW, Australia

B134 **AI-designed photo-immunolipid therapy (PILT) remodels the pancreatic tumor microenvironment to potentiate immune checkpoint blockade**, Girgis Obaid, University of Texas at Dallas, Richardson, TX, United States

B135 **The significance of third-line chemotherapy for pancreatic ductal adenocarcinoma: A single-center retrospective analysis**, Akihiro Ohba, Shizuoka Cancer Center, Shizuoka, , Japan

B136 **In Silico Screening and Biological Evaluation of Traditional Chinese Medicines library against Switch-II Pocket of KRASG12D in pancreatic Cancer**, Divya K Pandey, Graphic era hill university, Dehradun, UT, India

B137 **Targeting MICAL2 sensitizes pancreatic cancer cells to gemcitabine and enhances therapeutic response**, Ponmathi Panneerpandian, Moores Cancer Center, UCSD, San Diego, CA, United States

B138 **Biocompatible, injectable, and thermoresponsive nanoparticle-loaded hydrogel for the controlled release of FGFR irreversible inhibitor-1 of pancreatic perineural invasion**, Xenia Paolelli, Institute of Nanotechnology, National Research Council (CNR-NANOTEC), Lecce, , Italy

B139 **Targeting wild-type IDH1 creates a PARP inhibitor vulnerability in pancreatic cancer**, Parsa Rezvani, Case Western Reserve University, Cleveland, OH, United States

B140 **Irreversible electroporation and radiation therapy: Potential for combination therapy for locally advanced pancreatic cancer**, Himangshu Sonowal, Department of Surgery, Division of Surgical Oncology, Moores Cancer Center, University of California San Diego, CA, San Diego, CA, United States

B141 **Anti-Lymphocyte Antigen 6D (LY6D) monoclonal antibody inhibits pancreatic tumor growth in vivo by downregulating the TGFb-Smad2 signaling.**, Geeta Upadhyay, Uniformed Services University of Health Sciences, Bethesda, MD, United States

B142 **Legumain-activated pan-RAS/DXd dual-payload ADC for RAS-mutant, RAS-wild-type, and single-payload-resistant tumors**, CHAO WANG, Affinity Biopharmaceutical Co., Ltd., Shanghai, , China

B143 **Functional screening of Arid1a-deficient pancreatic adenocarcinoma using the MAPS platform**, Wenjia Wang, Wilmot Cancer Institute/University of Rochester Medical Center, Rochester, NY, United States

B144 **MUC16-directed DR5 activation by IMV-M induces selective tumor cell apoptosis and tumor regression and enhances the activity of KRAS inhibitors in preclinical pancreatic cancer models**, Matthew S Zucker, Translational Genomics Research Institute, Phoenix, AZ, United States